Identification and Characterization of the Direct Interaction between Methotrexate (MTX) and High-Mobility Group Box 1 (HMGB1) Protein

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Kuroiwa, Yuki ^a   Takakusagi, Yoichi ^a,b   Kusayanagi, Tomoe ^a   Kuramochi, Kouji ^a   Imai, Takahiko ^a   Hirayama, Tomoko ^a   Ito, Ichiaki ^a   Yoshida, Michiteru ^a   Sakaguchi, Kengo ^a   Sugawara, Fumio ^a  

^a TOKYO UNIVERSITY OF SCIENCE   (Japan)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; COAT PROTEIN; DRUG BINDING PROTEIN; HIGH MOBILITY GROUP B1 PROTEIN; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA; ANTINEOPLASTIC ANTIMETABOLITE; NONSTEROID ANTIINFLAMMATORY AGENT; PEPTIDE; PEPTIDE LIBRARY; PROTEIN BINDING;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BACTERIOPHAGE T7; BINDING AFFINITY; BINDING SITE; BIOTINYLATION; CONTROLLED STUDY; CYTOKINE RELEASE; DISSOCIATION CONSTANT; DNA SEQUENCE; DRUG PROTEIN BINDING; ENZYME INHIBITION; GEL MOBILITY SHIFT ASSAY; IN VITRO STUDY; MACROPHAGE; MITOGENESIS; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PHAGE DISPLAY; PROTEIN ANALYSIS; PROTEIN DNA BINDING; PROTEIN DOMAIN; PROTEIN INTERACTION; SURFACE PLASMON RESONANCE; AMINO ACID SEQUENCE; ANIMAL; BIOSYNTHESIS; CELL LINE; CHEMISTRY; CYTOLOGY; DRUG EFFECTS; ENTEROBACTERIA PHAGE T7; GENETICS; HUMAN; KINETICS; METABOLISM; MOLECULAR GENETICS; PEPTIDE LIBRARY; SECRETION (PROCESS);

MURINAE;

AMINO ACID SEQUENCE; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIMETABOLITES, ANTINEOPLASTIC; BACTERIOPHAGE T7; BINDING SITES; CELL LINE; ELECTROPHORETIC MOBILITY SHIFT ASSAY; HMGB1 PROTEIN; HUMANS; KINETICS; MACROPHAGES; METHOTREXATE; MICE; MOLECULAR SEQUENCE DATA; PEPTIDE LIBRARY; PEPTIDES; PROTEIN BINDING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84877063166     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0063073     Document Type: Article

References (40)

1. Swierkot J, Szechinski J, (2006) Methotrexate in rheumatoid arthritis. Pharmacol Rep 58: 473-492.
2. Gargaro AR, Soteriou A, Frenkiel TA, Bauer CJ, Birdsall B, et al. (1998) The solution structure of the complex of Lactobacillus casei dihydrofolate reductase with methotrexate. J Mol Biol 277: 119-134.
3. Uga H, Kuramori C, Ohta A, Tsuboi Y, Tanaka H, et al. (2006) A new mechanism of methotrexate action revealed by target screening with affinity beads. Mol Pharmacol 70: 1832-1839.
4. Majumdar S, Aggarwal BB, (2001) Methotrexate suppresses NF-kappaB activation through inhibition of IkappaBalpha phosphorylation and degradation. J Immunol 167: 2911-2920.
5. Takakusagi Y, Takakusagi K, Sugawara F, Sakaguchi K, (2010) Use of phage display technology for the determination of the targets for small-molecule therapeutics. Expert Opin Drug Discov 5: 361-389.
6. Harris HE, Andersson U, Pisetsky DS, (2012) HMGB1: a multifunctional alarmin driving autoimmune and inflammatory disease. Nat Rev Rheumatol 8: 195-202.
7. Ueda T, Yoshida M, (2010) HMGB proteins and transcriptional regulation. Biochim Biophys Acta 1799: 114-118.
8. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, et al. (1999) HMG-1 as a late mediator of endotoxin lethality in mice. Science 285: 248-251.
9. Hori O, Brett J, Slattery T, Cao R, Zhang J, et al. (1995) The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J Biol Chem 270: 25752-25761.
10. Fan J, Huennekens FM, (1997) Biotin derivatives of folate compounds: synthesis and utilization for visualization and affinity purification of folate transport proteins. Methods Enzymol 281: 97-105.
11. Fan J, Vitols KS, Huennekens FM, (1991) Biotin derivatives of methotrexate and folate. Synthesis and utilization for affinity purification of two membrane-associated folate transporters from L1210 cells. J Biol Chem 266: 14862-14865.
12. Novagen (2009) OrientExpressTM cDNA Manual. Novagen TB247: 1109JN.
13. Novagen (2009) T7 Select® System Manual. Novagen TB178: 1009JN.
14. Takakusagi Y, Kuroiwa Y, Sugawara F, Sakaguchi K, (2008) Identification of a methotrexate-binding peptide from a T7 phage display screen using a QCM device. Bioorg Med Chem 16: 7410-7414.
15. Saito K, Kikuchi T, Shirakawa H, Yoshida M, (1999) The stabilized structural array of two HMG1/2-boxes endowed by a linker sequence between them is requisite for the effective binding of HMG1 with DNA. J Biochem 125: 399-405.
16. Takakusagi Y, Takakusagi K, Ida N, Takami M, Matsumoto Y, et al. (2011) Binding region and interaction properties of sulfoquinovosylacylglycerol (SQAG) with human vascular endothelial growth factor 165 revealed by biosensor-based assays. Medchemcomm 2: 1188-1193.
17. Zierler K, (1989) Misuse of nonlinear Scatchard plots. Trends Biochem Sci 14: 314-317.
18. Goutelle S, Maurin M, Rougier F, Barbaut X, Bourguignon L, et al. (2008) The Hill equation: a review of its capabilities in pharmacological modelling. Fundam Clin Pharmacol 22: 633-648.
19. Hardman CH, Broadhurst RW, Raine AR, Grasser KD, Thomas JO, et al. (1995) Structure of the A-domain of HMG1 and its interaction with DNA as studied by heteronuclear three- and four-dimensional NMR spectroscopy. Biochemistry 34: 16596-16607.
20. Weir HM, Kraulis PJ, Hill CS, Raine AR, Laue ED, et al. (1993) Structure of the HMG box motif in the B-domain of HMG1. EMBO J 12: 1311-1319.
21. Stott K, Tang GS, Lee KB, Thomas JO, (2006) Structure of a complex of tandem HMG boxes and DNA. J Mol Biol 360: 90-104.
22. Yang H, Wang H, Czura CJ, Tracey KJ, (2005) The cytokine activity of HMGB1. J Leukoc Biol 78: 1-8.
23. Taniguchi N, Kawahara K, Yone K, Hashiguchi T, Yamakuchi M, et al. (2003) High mobility group box chromosomal protein 1 plays a role in the pathogenesis of rheumatoid arthritis as a novel cytokine. Arthritis Rheum 48: 971-981.
24. Park JS, Svetkauskaite D, He Q, Kim JY, Strassheim D, et al. (2004) Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem 279: 7370-7377.
25. Li J, Kokkola R, Tabibzadeh S, Yang R, Ochani M, et al. (2003) Structural basis for the proinflammatory cytokine activity of high mobility group box 1. Mol Med 9: 37-45.
26. Huttunen HJ, Fages C, Kuja-Panula J, Ridley AJ, Rauvala H, (2002) Receptor for advanced glycation end products-binding COOH-terminal motif of amphoterin inhibits invasive migration and metastasis. Cancer Res 62: 4805-4811.
27. Yamamoto A, Ando Y, Yoshioka K, Saito K, Tanabe T, et al. (1997) Difference in affinity for DNA between HMG proteins 1 and 2 determined by surface plasmon resonance measurements. J Biochem 122: 586-594.
28. Hreggvidsdottir HS, Lundberg AM, Aveberger AC, Klevenvall L, Andersson U, et al. (2012) High mobility group box protein 1 (HMGB1)-partner molecule complexes enhance cytokine production by signaling through the partner molecule receptor. Mol Med 18: 224-230.
29. Yang H, Hreggvidsdottir HS, Palmblad K, Wang H, Ochani M, et al. (2010) A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine release. Proc Natl Acad Sci U S A 107: 11942-11947.
30. Youn JH, Kwak MS, Wu J, Kim ES, Ji Y, et al. (2011) Identification of lipopolysaccharide-binding peptide regions within HMGB1 and their effects on subclinical endotoxemia in a mouse model. Eur J Immunol 41: 2753-2762.
31. Schierbeck H, Wahamaa H, Andersson U, Harris HE, (2010) Immunomodulatory drugs regulate HMGB1 release from activated human monocytes. Mol Med 16: 343-351.
32. Mollica L, De Marchis F, Spitaleri A, Dallacosta C, Pennacchini D, et al. (2007) Glycyrrhizin binds to high-mobility group box 1 protein and inhibits its cytokine activities. Chem Biol 14: 431-441.
33. Andersson U, Wang H, Palmblad K, Aveberger AC, Bloom O, et al. (2000) High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med 192: 565-570.
34. Kokkola R, Andersson A, Mullins G, Ostberg T, Treutiger CJ, et al. (2005) RAGE is the major receptor for the proinflammatory activity of HMGB1 in rodent macrophages. Scand J Immunol 61: 1-9.
35. Palumbo R, Sampaolesi M, De Marchis F, Tonlorenzi R, Colombetti S, et al. (2004) Extracellular HMGB1, a signal of tissue damage, induces mesoangioblast migration and proliferation. J Cell Biol 164: 441-449.
36. Huttunen HJ, Rauvala H, (2004) Amphoterin as an extracellular regulator of cell motility: from discovery to disease. J Intern Med 255: 351-366.
37. Smolen JS, Landewe R, Breedveld FC, Dougados M, Emery P, et al. (2010) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 69: 964-975.
38. Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, et al. (2010) Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 69: 631-637.
39. Visser K, Katchamart W, Loza E, Martinez-Lopez JA, Salliot C, et al. (2009) Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis 68: 1086-1093.
40. Wallace CA, Bleyer WA, Sherry DD, Salmonson KL, Wedgwood RJ, (1989) Toxicity and serum levels of methotrexate in children with juvenile rheumatoid arthritis. Arthritis Rheum 32: 677-681.